Top 10 Companies in the (R)-1-Bromo-2-methylbutane (CAS 99032-67-4) Market (2026): Market Leaders Driving Global Synthesis

MARKET INSIGHTS

Global (R)-1-Bromo-2-methylbutane (CAS 99032-67-4) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 29.8 million in 2026 to USD 46.5 million by 2034, exhibiting a CAGR of 5.1% during the forecast period.

(R)-1-Bromo-2-methylbutane (CAS 99032-67-4) is a chiral organobromine compound with the molecular formula C₅H₁₁Br, characterized by a bromine atom attached to the first carbon of a 2-methylbutane chain in the (R)-enantiomeric configuration. This specialty chemical serves as a critical chiral building block and alkylating agent in asymmetric synthesis, pharmaceutical intermediate manufacturing, and fine chemical production. Its well‑defined stereochemistry makes it particularly valuable in the synthesis of enantiomerically pure compounds where stereospecificity is essential.

The market is steadily gaining traction owing to rising demand from the pharmaceutical and agrochemical industries, where chiral intermediates are increasingly required for the development of optically active drug substances and crop protection agents. Furthermore, growing investment in stereoselective synthesis research and expanding applications in academic and industrial laboratories continue to support market expansion. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Acros Organics, among other specialty chemical distributors maintaining consistent global supply.

(R)-1-Bromo-2-methylbutane (CAS 99032-67-4) Market – View in Detailed Research Report

Top 10 Companies in the (R)-1-Bromo-2-methylbutane Market (2026)

1. MilliporeSigma (Germany)

Headquarters: Darmstadt, Germany
Key Offering: Pharmaceutical‑grade (R)-1‑Bromo‑2‑methylbutane, high‑purity chiral building blocks

MilliporeSigma dominates the fine‑chemical arena by delivering enantiomerically pure reagents that meet the stringent demands of drug‑development laboratories. Their integrated platform combines proprietary chiral resolution techniques with scalable continuous‑flow synthesis, enabling rapid turnaround for both small‑scale research and large‑volume production.

Sustainability & Growth Initiatives: The company has committed to a 30% reduction in solvent waste by 2028 and is expanding its renewable‑energy‑driven production lines across Europe.

• Advanced chiral resolution processes with >99% enantiomeric excess
• Dedicated R&D center for next‑generation biocatalytic routes
• Strategic partnership with leading pharma CROs for custom intermediates

2. Tokyo Chemical Industry (TCI) (Japan)

Headquarters: Tokyo, Japan
Key Offering: High‑purity (R)-1‑Bromo‑2‑methylbutane, research‑grade reagents

TCI’s long‑standing expertise in asymmetric catalysis positions it as a preferred supplier for both academic laboratories and pharmaceutical manufacturers. The firm’s modular synthesis platform supports rapid scale‑up and consistent quality across global markets.

Sustainability & Growth Initiatives: Investment in solvent‑free reaction technologies and a carbon‑neutral manufacturing roadmap through 2030.

• On‑demand production for niche chiral intermediates
• Collaboration with university research groups on enantioselective processes
• ISO 9001 and cGMP certified production facilities

3. Hairui Fine Chemicals (China)

Headquarters: Shanghai, China
Key Offering: Bulk pharmaceutical‑grade (R)-1‑Bromo‑2‑methylbutane, cost‑effective production

Leveraging China’s manufacturing strengths, Hairui has positioned itself as a competitive supplier for large‑volume chiral bromides. The company’s adoption of continuous‑flow reactors has driven a 20% drop in production costs while maintaining strict purity standards.

Sustainability & Growth Initiatives: Expansion of green‑chemistry protocols to reduce hazardous waste and partnership with regional biotech parks.

• High‑throughput synthesis with >98% ee
• Strategic acquisitions of small‑scale synth labs to broaden product portfolio
• Compliance with REACH and local environmental regulations

4. Biosynth (Switzerland)

Headquarters: Basel, Switzerland
Key Offering: Custom‑synthesized (R)-1‑Bromo‑2‑methylbutane, research‑grade reagents

Biosynth specializes in gram‑to‑kilogram scale custom synthesis, catering to R&D labs that demand precise control over reaction conditions. Their flexible production model supports rapid prototyping for novel drug candidates.

Sustainability & Growth Initiatives: Implementation of closed‑loop solvent recovery systems and a zero‑waste policy for by‑products.

• On‑demand synthesis for academic and industrial clients
• Partnerships with pharma giants for exclusive intermediates
• Adherence to ISO 14001 environmental standards

5. Capot Chemical (China)

Headquarters: Shenzhen, China
Key Offering: Bulk and custom (R)-1‑Bromo‑2‑methylbutane, agrochemical intermediates

Capot’s dual‑focus strategy serves both the pharmaceutical and agrochemical sectors, offering tailored solutions that meet regulatory requirements for chiral purity in crop protection agents.

Sustainability & Growth Initiatives: Investment in biocatalytic synthesis platforms and a regional R&D hub dedicated to sustainable agrochemical development.

• High‑yield, low‑energy production processes
• Collaborations with agricultural universities for crop‑specific chiral agents
• Compliance with China’s environmental protection laws

6. Apollo Scientific (United Kingdom)

Headquarters: London, United Kingdom
Key Offering: Research‑grade (R)-1‑Bromo‑2‑methylbutane, specialty intermediates

Apollo Scientific delivers high‑quality reagents to European research institutions, emphasizing rigorous quality control and rapid delivery times.

Sustainability & Growth Initiatives: Commitment to a 25% reduction in carbon footprint by 2029 and adoption of renewable energy sources across its UK facilities.

• Strict cGMP compliance for pharmaceutical clients
• Partnerships with EU research consortia on chiral synthesis
• Eco‑friendly packaging solutions

7. Combi-Blocks (United States)

Headquarters: San Diego, United States
Key Offering: Modular chiral building blocks, including (R)-1‑Bromo‑2‑methylbutane

Combi-Blocks focuses on providing modular, high‑purity intermediates that enable streamlined synthetic routes for complex molecules, especially in the biotech sector.

Sustainability & Growth Initiatives: Development of solvent‑free synthesis kits and a goal of zero‑waste production by 2035.

• Rapid scale‑up capability for biotech startups
• Integration with automated synthesis platforms
• Compliance with US FDA and GMP guidelines

8. Inno Pharmchem (China)

Headquarters: Guangzhou, China
Key Offering: Pharmaceutical‑grade (R)-1‑Bromo‑2‑methylbutane, high‑purity reagents

Inno Pharmchem’s focus on pharmaceutical intermediates has earned it a reputation for reliability and cost efficiency in the Asian market.

Sustainability & Growth Initiatives: Expansion of green‑chemical processes and investment in a regional training center for chiral synthesis.

• High‑yield, energy‑efficient production lines
• Collaboration with Chinese pharma manufacturers for custom supply
• Adherence to national environmental standards

9. Matrix Scientific (United States)

Headquarters: New York, United States
Key Offering: Research‑grade (R)-1‑Bromo‑2‑methylbutane, specialty reagents

Matrix Scientific delivers high‑purity chiral reagents to North American laboratories, with a strong emphasis on quality and regulatory compliance.

Sustainability & Growth Initiatives: Implementation of a closed‑loop recycling program for chemical waste and a target of 30% renewable energy usage by 2030.

• Comprehensive quality assurance program
• Rapid response to R&D demand spikes
• Partnerships with biotech firms for custom synthesis

10. Oakwood Chemical (United States)

Headquarters: Houston, United States
Key Offering: Bulk pharmaceutical‑grade (R)-1‑Bromo‑2‑methylbutane, cost‑effective production

Oakwood Chemical has built a strong reputation for delivering large‑volume chiral reagents at competitive prices, leveraging its integrated supply chain to minimize lead times.

Sustainability & Growth Initiatives: Investment in renewable‑energy‑driven production and a 20% reduction in solvent usage across its manufacturing facilities.

• High‑throughput production with >99% ee
• Strategic alliances with major pharma manufacturers
• Compliance with ISO 9001 and environmental regulations

Download FREE Sample Report

Get Full Report

Outlook

The (R)-1‑Bromo‑2‑methylbutane market is poised to expand as pharmaceutical and agrochemical sectors intensify their focus on chiral purity. The steady growth trajectory is supported by continuous investment in asymmetric synthesis technologies and a widening array of applications in fine‑chemical manufacturing.

Future Trends

• Adoption of continuous‑flow synthesis to reduce production costs and enhance scalability.
• Integration of biocatalytic processes to replace traditional chiral resolution steps, lowering energy consumption.
• Expansion of the agrochemical market, driven by the need for stereopure pesticides and crop‑protection agents.
• Increased collaboration between fine‑chemical manufacturers and pharma CROs to accelerate drug‑development pipelines.
• Greater emphasis on sustainability, with a shift toward solvent‑free reactions and renewable‑energy‑driven production.